Cytokinetics (CYTK) EBIT Margin (2016 - 2024)
Historic EBIT Margin for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to 1555.61%.
- Cytokinetics' EBIT Margin rose 91763000.0% to 1555.61% in Q4 2024 from the same period last year, while for Dec 2024 it was 7255.42%, marking a year-over-year increase of 138451300.0%. This contributed to the annual value of 1422.37% for FY2024, which is 80120800.0% up from last year.
- Cytokinetics' EBIT Margin amounted to 1555.61% in Q4 2024, which was up 91763000.0% from 30410.58% recorded in Q3 2024.
- In the past 5 years, Cytokinetics' EBIT Margin registered a high of 1555.61% during Q4 2024, and its lowest value of 52277.91% during Q2 2024.
- Its 5-year average for EBIT Margin is 8792.85%, with a median of 2312.87% in 2023.
- Within the past 5 years, the most significant YoY rise in Cytokinetics' EBIT Margin was 91763000bps (2024), while the steepest drop was -382007500bps (2024).
- Over the past 5 years, Cytokinetics' EBIT Margin (Quarter) stood at 288.81% in 2020, then tumbled by -119bps to 54.16% in 2021, then plummeted by -11884bps to 6491.06% in 2022, then decreased by -17bps to 7620.69% in 2023, then skyrocketed by 120bps to 1555.61% in 2024.
- Its EBIT Margin stands at 1555.61% for Q4 2024, versus 30410.58% for Q3 2024 and 52277.91% for Q2 2024.